A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain
Phase 3
Completed
NCT05661734
| Condition | Pain |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Vertex Pharmaceuticals Incorporated |
|---|
| Status | Completed |
|---|
| Enrollment | 258 participants |
|---|
| Interventions | Suzetrigine |
|---|
| Start date | Jan 9, 2023 |
|---|
| Completion date | Dec 12, 2023 |
|---|
| Results posted | Jul 1, 2025 |
|---|
Summary
The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Day 1 up to Day 30 · Participants
| Suzetrigine (SUZ) | 94 Participants |
|---|
| Suzetrigine (SUZ) | 2 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.